AML in the elderly-A global view

Affiliations

¹ Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
² Fundación para Combatir la Leucemia, Department of Hematology, Buenos Aires, Argentina.
³ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
⁴ Department of Clinical Science, Haukeland Centre for Cancer Biomarkers (CCBIO), University of Bergen, Helse Bergen HF, Bergen, Norway.
⁵ Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Helse Bergen HF, Bergen, Norway.
⁶ Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
⁷ Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, UK.
⁸ Department of Hematology and Oncology, Nagoya City University East Medical Center, Nagoya, Japan.
⁹ Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Review

Peter Hokland et al. Br J Haematol. 2023 Dec.

. 2023 Dec;203(5):760-773.

doi: 10.1111/bjh.19135. Epub 2023 Oct 11.

¹ Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
² Fundación para Combatir la Leucemia, Department of Hematology, Buenos Aires, Argentina.
³ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
⁴ Department of Clinical Science, Haukeland Centre for Cancer Biomarkers (CCBIO), University of Bergen, Helse Bergen HF, Bergen, Norway.
⁵ Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Helse Bergen HF, Bergen, Norway.
⁶ Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
⁷ Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, UK.
⁸ Department of Hematology and Oncology, Nagoya City University East Medical Center, Nagoya, Japan.
⁹ Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

No abstract available

Keywords: acute myeloid leukaemia; elderly; global view; leukaemia diagnosis; minimal residual disease.

Comment in

Rounding off our Global View series.
Hokland P. Hokland P. Br J Haematol. 2023 Dec;203(5):710-711. doi: 10.1111/bjh.19172. Epub 2023 Nov 1. Br J Haematol. 2023. PMID: 37909166

1. Hokland P. AML-a signature disease in haematology. Br J Haematol. 2020;188(1):7.
1. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.
1. Yanada M, Terakura S, Yokozawa T, Yamamoto K, Kiyoi H, Emi N, et al. Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. Leuk Lymphoma. 2004;45(9):1803-1808.
1. Mehta P, Telford N, Wragg C, Dillon R, Freeman S, Finnegan D, et al. Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. Br J Haematol. 2023;200(2):150-159.
1. Ferrara F, Barosi G, Venditti A, Angelucci E, Gobbi M, Pane F, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27(5):997-999.